British biotech firm secures coveted FDA designation in bid to develop world's first treatment for rare, incurable and deadly disease

A leading UK biotech firm founded to develop the world’s first treatment for a rare, incurable and deadly disease has secured its first Food and Drug Administration (FDA) designation. SynaptixBio, which aims to tackle TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and ...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,United Kingdom ,Switzerland ,Swiss ,Dan Williams ,Adeline Vanderver ,Leukodystrophy Center ,University Of Utah ,Drug Administration ,Novartis ,Rare Paediatric Disease ,